Advances and challenges in PBPK modeling–Analysis of factors contributing to the oral absorption of atazanavir, a poorly soluble weak base. Berlin, M., Ruff, A., Kesisoglou, F., Xu, W., Wang, M. H., & Dressman, J. B. Eur J Pharm Biopharm, 93:267–80, June, 2015. doi abstract bibtex Many active pharmaceutical ingredients (APIs) exhibit a highly variable pharmacokinetic (PK) profile. This behavior may be attributable to pre-absorptive, absorptive and/or post-absorptive factors. Pre-absorptive factors are those related to dosage form disintegration, drug dissolution, supersaturation, precipitation and gastric emptying. Absorptive factors are involved with drug absorption and efflux mechanisms, while drug distribution and clearance are post-absorptive factors. This study aimed to investigate the relative influence of the aforementioned parameters on the pharmacokinetic profile of atazanavir, a poorly soluble weakly basic compound with highly variable pharmacokinetics. The pre-absorptive behavior of the drug was examined by applying biorelevant in vitro tests to reflect upper gastrointestinal behavior in the fasted and fed states. The in vitro results were implemented, along with permeability and post-absorptive data obtained from the literature, into physiologically based pharmacokinetic (PBPK) models. Sensitivity analysis of the resulting plasma profiles revealed that the pharmacokinetic profile of atazanavir is affected by an array of factors rather than one standout factor. According to the in silico model, pre-absorptive and absorptive factors had less impact on atazanavir bioavailability compared to post-absorptive parameters, although active drug efflux and extraction appear to account for the sub-proportional pharmacokinetic response to lower atazanavir doses in the fasted state. From the PBPK models it was concluded that further enhancement of the formulation would bring little improvement in the pharmacokinetic response to atazanavir. This approach may prove useful in assessing the potential benefits of formulation enhancement of other existing drug products on the market.
@article{berlin_advances_2015,
title = {Advances and challenges in {PBPK} modeling--{Analysis} of factors contributing to the oral absorption of atazanavir, a poorly soluble weak base},
volume = {93},
issn = {1873-3441 (Electronic) 0939-6411 (Linking)},
doi = {10.1016/j.ejpb.2015.03.031},
abstract = {Many active pharmaceutical ingredients (APIs) exhibit a highly variable pharmacokinetic (PK) profile. This behavior may be attributable to pre-absorptive, absorptive and/or post-absorptive factors. Pre-absorptive factors are those related to dosage form disintegration, drug dissolution, supersaturation, precipitation and gastric emptying. Absorptive factors are involved with drug absorption and efflux mechanisms, while drug distribution and clearance are post-absorptive factors. This study aimed to investigate the relative influence of the aforementioned parameters on the pharmacokinetic profile of atazanavir, a poorly soluble weakly basic compound with highly variable pharmacokinetics. The pre-absorptive behavior of the drug was examined by applying biorelevant in vitro tests to reflect upper gastrointestinal behavior in the fasted and fed states. The in vitro results were implemented, along with permeability and post-absorptive data obtained from the literature, into physiologically based pharmacokinetic (PBPK) models. Sensitivity analysis of the resulting plasma profiles revealed that the pharmacokinetic profile of atazanavir is affected by an array of factors rather than one standout factor. According to the in silico model, pre-absorptive and absorptive factors had less impact on atazanavir bioavailability compared to post-absorptive parameters, although active drug efflux and extraction appear to account for the sub-proportional pharmacokinetic response to lower atazanavir doses in the fasted state. From the PBPK models it was concluded that further enhancement of the formulation would bring little improvement in the pharmacokinetic response to atazanavir. This approach may prove useful in assessing the potential benefits of formulation enhancement of other existing drug products on the market.},
journal = {Eur J Pharm Biopharm},
author = {Berlin, M. and Ruff, A. and Kesisoglou, F. and Xu, W. and Wang, M. H. and Dressman, J. B.},
month = jun,
year = {2015},
keywords = {*Gastrointestinal Absorption, *Models, Biological, Absorption, Administration, Oral, Adolescent, Adult, Atazanavir, Atazanavir Sulfate/*administration \& dosage/blood/chemistry/*pharmacokinetics, Biological Availability, Chemistry, Pharmaceutical, Computer Simulation, Dissolution, Fasting/metabolism, Formulation development, Gastric Juice/chemistry, Gastric emptying, HIV Protease Inhibitors/*administration \&, Humans, Hydrogen-Ion Concentration, Intestinal Secretions/chemistry, Male, Permeability, Pharmacokinetics, Physiologically based pharmacokinetic model, Postprandial Period, Precipitation, Solubility, Supersaturation, Technology, Pharmaceutical/methods, Young Adult, dosage/blood/chemistry/*pharmacokinetics},
pages = {267--80},
}
Downloads: 0
{"_id":"67j8F7utasuZg9f56","bibbaseid":"berlin-ruff-kesisoglou-xu-wang-dressman-advancesandchallengesinpbpkmodelinganalysisoffactorscontributingtotheoralabsorptionofatazanavirapoorlysolubleweakbase-2015","author_short":["Berlin, M.","Ruff, A.","Kesisoglou, F.","Xu, W.","Wang, M. H.","Dressman, J. B."],"bibdata":{"bibtype":"article","type":"article","title":"Advances and challenges in PBPK modeling–Analysis of factors contributing to the oral absorption of atazanavir, a poorly soluble weak base","volume":"93","issn":"1873-3441 (Electronic) 0939-6411 (Linking)","doi":"10.1016/j.ejpb.2015.03.031","abstract":"Many active pharmaceutical ingredients (APIs) exhibit a highly variable pharmacokinetic (PK) profile. This behavior may be attributable to pre-absorptive, absorptive and/or post-absorptive factors. Pre-absorptive factors are those related to dosage form disintegration, drug dissolution, supersaturation, precipitation and gastric emptying. Absorptive factors are involved with drug absorption and efflux mechanisms, while drug distribution and clearance are post-absorptive factors. This study aimed to investigate the relative influence of the aforementioned parameters on the pharmacokinetic profile of atazanavir, a poorly soluble weakly basic compound with highly variable pharmacokinetics. The pre-absorptive behavior of the drug was examined by applying biorelevant in vitro tests to reflect upper gastrointestinal behavior in the fasted and fed states. The in vitro results were implemented, along with permeability and post-absorptive data obtained from the literature, into physiologically based pharmacokinetic (PBPK) models. Sensitivity analysis of the resulting plasma profiles revealed that the pharmacokinetic profile of atazanavir is affected by an array of factors rather than one standout factor. According to the in silico model, pre-absorptive and absorptive factors had less impact on atazanavir bioavailability compared to post-absorptive parameters, although active drug efflux and extraction appear to account for the sub-proportional pharmacokinetic response to lower atazanavir doses in the fasted state. From the PBPK models it was concluded that further enhancement of the formulation would bring little improvement in the pharmacokinetic response to atazanavir. This approach may prove useful in assessing the potential benefits of formulation enhancement of other existing drug products on the market.","journal":"Eur J Pharm Biopharm","author":[{"propositions":[],"lastnames":["Berlin"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["Ruff"],"firstnames":["A."],"suffixes":[]},{"propositions":[],"lastnames":["Kesisoglou"],"firstnames":["F."],"suffixes":[]},{"propositions":[],"lastnames":["Xu"],"firstnames":["W."],"suffixes":[]},{"propositions":[],"lastnames":["Wang"],"firstnames":["M.","H."],"suffixes":[]},{"propositions":[],"lastnames":["Dressman"],"firstnames":["J.","B."],"suffixes":[]}],"month":"June","year":"2015","keywords":"*Gastrointestinal Absorption, *Models, Biological, Absorption, Administration, Oral, Adolescent, Adult, Atazanavir, Atazanavir Sulfate/*administration & dosage/blood/chemistry/*pharmacokinetics, Biological Availability, Chemistry, Pharmaceutical, Computer Simulation, Dissolution, Fasting/metabolism, Formulation development, Gastric Juice/chemistry, Gastric emptying, HIV Protease Inhibitors/*administration &, Humans, Hydrogen-Ion Concentration, Intestinal Secretions/chemistry, Male, Permeability, Pharmacokinetics, Physiologically based pharmacokinetic model, Postprandial Period, Precipitation, Solubility, Supersaturation, Technology, Pharmaceutical/methods, Young Adult, dosage/blood/chemistry/*pharmacokinetics","pages":"267–80","bibtex":"@article{berlin_advances_2015,\n\ttitle = {Advances and challenges in {PBPK} modeling--{Analysis} of factors contributing to the oral absorption of atazanavir, a poorly soluble weak base},\n\tvolume = {93},\n\tissn = {1873-3441 (Electronic) 0939-6411 (Linking)},\n\tdoi = {10.1016/j.ejpb.2015.03.031},\n\tabstract = {Many active pharmaceutical ingredients (APIs) exhibit a highly variable pharmacokinetic (PK) profile. This behavior may be attributable to pre-absorptive, absorptive and/or post-absorptive factors. Pre-absorptive factors are those related to dosage form disintegration, drug dissolution, supersaturation, precipitation and gastric emptying. Absorptive factors are involved with drug absorption and efflux mechanisms, while drug distribution and clearance are post-absorptive factors. This study aimed to investigate the relative influence of the aforementioned parameters on the pharmacokinetic profile of atazanavir, a poorly soluble weakly basic compound with highly variable pharmacokinetics. The pre-absorptive behavior of the drug was examined by applying biorelevant in vitro tests to reflect upper gastrointestinal behavior in the fasted and fed states. The in vitro results were implemented, along with permeability and post-absorptive data obtained from the literature, into physiologically based pharmacokinetic (PBPK) models. Sensitivity analysis of the resulting plasma profiles revealed that the pharmacokinetic profile of atazanavir is affected by an array of factors rather than one standout factor. According to the in silico model, pre-absorptive and absorptive factors had less impact on atazanavir bioavailability compared to post-absorptive parameters, although active drug efflux and extraction appear to account for the sub-proportional pharmacokinetic response to lower atazanavir doses in the fasted state. From the PBPK models it was concluded that further enhancement of the formulation would bring little improvement in the pharmacokinetic response to atazanavir. This approach may prove useful in assessing the potential benefits of formulation enhancement of other existing drug products on the market.},\n\tjournal = {Eur J Pharm Biopharm},\n\tauthor = {Berlin, M. and Ruff, A. and Kesisoglou, F. and Xu, W. and Wang, M. H. and Dressman, J. B.},\n\tmonth = jun,\n\tyear = {2015},\n\tkeywords = {*Gastrointestinal Absorption, *Models, Biological, Absorption, Administration, Oral, Adolescent, Adult, Atazanavir, Atazanavir Sulfate/*administration \\& dosage/blood/chemistry/*pharmacokinetics, Biological Availability, Chemistry, Pharmaceutical, Computer Simulation, Dissolution, Fasting/metabolism, Formulation development, Gastric Juice/chemistry, Gastric emptying, HIV Protease Inhibitors/*administration \\&, Humans, Hydrogen-Ion Concentration, Intestinal Secretions/chemistry, Male, Permeability, Pharmacokinetics, Physiologically based pharmacokinetic model, Postprandial Period, Precipitation, Solubility, Supersaturation, Technology, Pharmaceutical/methods, Young Adult, dosage/blood/chemistry/*pharmacokinetics},\n\tpages = {267--80},\n}\n\n","author_short":["Berlin, M.","Ruff, A.","Kesisoglou, F.","Xu, W.","Wang, M. H.","Dressman, J. B."],"key":"berlin_advances_2015","id":"berlin_advances_2015","bibbaseid":"berlin-ruff-kesisoglou-xu-wang-dressman-advancesandchallengesinpbpkmodelinganalysisoffactorscontributingtotheoralabsorptionofatazanavirapoorlysolubleweakbase-2015","role":"author","urls":{},"keyword":["*Gastrointestinal Absorption","*Models","Biological","Absorption","Administration","Oral","Adolescent","Adult","Atazanavir","Atazanavir Sulfate/*administration & dosage/blood/chemistry/*pharmacokinetics","Biological Availability","Chemistry","Pharmaceutical","Computer Simulation","Dissolution","Fasting/metabolism","Formulation development","Gastric Juice/chemistry","Gastric emptying","HIV Protease Inhibitors/*administration &","Humans","Hydrogen-Ion Concentration","Intestinal Secretions/chemistry","Male","Permeability","Pharmacokinetics","Physiologically based pharmacokinetic model","Postprandial Period","Precipitation","Solubility","Supersaturation","Technology","Pharmaceutical/methods","Young Adult","dosage/blood/chemistry/*pharmacokinetics"],"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/qingyuhms","dataSources":["uJZG8wcPfTAfBw67Z"],"keywords":["*gastrointestinal absorption","*models","biological","absorption","administration","oral","adolescent","adult","atazanavir","atazanavir sulfate/*administration & dosage/blood/chemistry/*pharmacokinetics","biological availability","chemistry","pharmaceutical","computer simulation","dissolution","fasting/metabolism","formulation development","gastric juice/chemistry","gastric emptying","hiv protease inhibitors/*administration &","humans","hydrogen-ion concentration","intestinal secretions/chemistry","male","permeability","pharmacokinetics","physiologically based pharmacokinetic model","postprandial period","precipitation","solubility","supersaturation","technology","pharmaceutical/methods","young adult","dosage/blood/chemistry/*pharmacokinetics"],"search_terms":["advances","challenges","pbpk","modeling","analysis","factors","contributing","oral","absorption","atazanavir","poorly","soluble","weak","base","berlin","ruff","kesisoglou","xu","wang","dressman"],"title":"Advances and challenges in PBPK modeling–Analysis of factors contributing to the oral absorption of atazanavir, a poorly soluble weak base","year":2015}